European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Aimmune Therapeutics (AIMT) PT Raised to $58 at RBC Capital
March 26, 2019 6:27 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $58.00 (from $55.00) while maintaining a Outperform rating.
ARTEMIS reads out positively in Europesetting the stage for a mid-19 MAA filing... MoreBaird Incrementally Positive on Aimmune Therapeutics (AIMT) ARTEMIS Topline Readout
March 25, 2019 12:52 PM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $64.00 price target on Aimmune Therapeutics (NASDAQ: AIMT) saying they are incrementally positive on ARTEMIS topline readout.
Skorney commented, "Aimmune announced today that the Phase 3 European trial of AR101 met its primary endpoint,... More
